GE Healthcare's ultrasound enhancing agent can be stored at room temperature for up to 24 hours GE Healthcare

Optison is an ultrasound enhancing agent manufactured in-house by
GE Healthcare.

Optison can provide added efficiency, portability, and storage flexibility. It may be stored at room temperature for up to 24 hours and returned safely to refrigeration.

Optison is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricle and to improve the delineation of the left ventricular endocardial borders.

Want to learn more about Optison?

Learn more Button


How does Optison help with workflow efficiency and portability?
  • Optison is the only ultrasound enhancing agent that does not require a device or specific equipment to prepare or activate
  • Optison has a highly consistent microsphere size, and simple preparation by rocking and rolling between the palms of your hands ensures a high level of suspended microspheres
  • Vials can go directly from storage to cart without premixing
  • If unopened and at room temperature up to 24 hours, Optison may be returned safely to refrigeration for use at a later time
  • For bolus injections, Optison takes <1 minute from suspension to injection in three steps: prepare, check, and load syringe

Want to learn more about how Optison can help with workflow efficiency?

Learn more Button


Do you have questions for our Optison team? Click the image below to contact us.

Contact us - click the image

IMPORTANT SAFETY INFORMATION
WARNING:
SERIOUS CARDIOPULMONARY REACTIONS
Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following perflutren-containing microsphere administration. Most serious reactions occur within 30 minutes of administration.
  • Assess all patients for the presence of any condition that precludes Optison administration
  • Always have resuscitation equipment and trained personnel readily available

CONTRAINDICATION: Do not administer Optison to patients with known or suspected hypersensitivity to perflutren, blood, blood products, or albumin.
  • WARNINGS AND PRECAUTIONS: Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or shortly following administration. The risk for these reactions may be increased among patients with unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias).
  • Serious anaphylactic reactions have been observed during or shortly following perflutren-containing microsphere administration, including shock, hypersensitivity, bronchospasm, throat tightness, angioedema, edema (pharyngeal, palatal, mouth, peripheral, localized), swelling (face, eye, lip, tongue, upper airway), facial hypoesthesia, rash, urticaria, pruritus, flushing, and erythema have occurred in patients with no prior exposure to perflutren-containing microsphere products.
  • When administering Optison to patients with a cardiac shunt, microspheres can bypass filtering of the lungs and enter the arterial circulation. Assess patients with shunts for embolic phenomena following Optison administration.
  • High ultrasound mechanical index values may cause microsphere rupture and lead to ventricular arrhythmias. Additionally, end-systolic triggering with high mechanical indices has been reported to cause ventricular arrhythmias. Optison is not recommended for use at mechanical indices greater than 0.8.
  • This product contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral disease.
  • ADVERSE EVENTS: The most frequently reported adverse reactions in clinical trials were headache, nausea and/or vomiting, warm sensation or flushing and dizziness. Cardiac arrests and other serious but nonfatal adverse reactions were uncommonly reported in post-approval use. Reports also identified neurologic reactions (loss of consciousness or convulsions) as well as anaphylactoid reactions.

To report SUSPECTED ADVERSE REACTIONS, contact GE Healthcare at 800 654 0118 (option 2, then option 1), or the FDA at 800 FDA 1088 or www.fda.gov/medwatch.
Please read the full Prescribing Information here, for additional important safety information.

© 2021 General Electric Company.
GE, the GE Monogram, and Optison are trademarks of General Electric Company.
Any third-party trademarks are the property of their respective owners.
April 2021 JB00932US

                                         
•  Do not reply to this email as it was sent from an unmonitored account.
 
•  Unsubscribe from the Breaking News.
 
•  Reset your password.
 
•  Contact AuntMinnie.com support.
 
•  AuntMinnie.com Privacy Policy.
 
•  Email sent to: .

AuntMinnie.com, 1350 North Kolb Road, Suite 215, Tucson, AZ 85715 USA
+1 520-298-1000